multiple sclerosis

Study Shows How Pharmaceutical Companies Maneuver To Maintain Sales, High Prices

This article is for premium subscribers!

To read further, please sign up for a premium subscription. You can also read more about standard and premium subscriptions here. Your subscription dollars are tax deductible and support the in-depth stories you appreciate from The Lund Report. If you believe you already are a premium subscriber, you are already logged in, and you are getting this message, please contact [email protected] Thanks!

If you are a premium subscriber that is not logged in, please login now.

When a generic multiple sclerosis drug hit the U.S. market in 2015, observers expected it could push down prices in a class of drugs that has skyrocketed in recent years. 

That did not happen. 

OHSU Study: Misdiagnosis of MS is Costing Health System Millions Per Year

The Lund Report
Study finds most MS experts surveyed have seen patients in last year who've been misdiagnosed

May 9, 2012 -- It is relatively common for doctors to diagnose someone
with multiple sclerosis when the patient doesn't have the disease — a
misdiagnosis that not only causes patients potential harm but costs the
U.S. health care system untold millions of dollars a year, according to a
study published online today in the journal Neurology.

The study is based on a survey of 122 multiple sclerosis specialists
nationwide and was conducted by researchers at Oregon Health
& Science University and the Portland Veterans Affairs Medical

Subscribe to multiple sclerosis